Aclaris Therapeutics Files 2024 Annual Report

Ticker: ACRS · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1557746

Aclaris Therapeutics, INC. 10-K Filing Summary
FieldDetail
CompanyAclaris Therapeutics, INC. (ACRS)
Form Type10-K
Filed DateFeb 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Aclaris Therapeutics filed its 2024 10-K. All systems go for pharma prep.

AI Summary

Aclaris Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Wayne, PA, operates in the pharmaceutical preparations sector. Key financial data and business operations for the period are detailed in this annual report.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Aclaris Therapeutics' financial health, operational performance, and strategic direction for the past fiscal year.

Risk Assessment

Risk Level: low — This is a standard annual financial filing with no immediate red flags.

Key Numbers

Key Players & Entities

FAQ

What were Aclaris Therapeutics' total revenues for the fiscal year ending December 31, 2024?

The provided snippet does not contain specific revenue figures for the fiscal year ending December 31, 2024.

What is the company's primary business activity as indicated by its SIC code?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted to the SEC on February 27, 2025.

What is the company's principal executive office location?

The company's principal executive office is located at 701 Lee Road, Suite 103, Wayne, PA 19087.

Does the filing mention any private placement transactions?

Yes, the filing indicates a private placement transaction occurred between November 1, 2024, and November 30, 2024.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Aclaris Therapeutics, Inc. (ACRS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing